Corbus Pharmaceuticals Holdings, Inc.
CRBP
$8.83
-$0.22-2.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 70.10M | 60.48M | 50.42M | 42.10M | 32.22M |
| Gross Profit | -70.10M | -60.48M | -50.42M | -42.10M | -32.22M |
| SG&A Expenses | 15.22M | 15.47M | 16.61M | 16.77M | 16.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.12M | -1.12M | -1.12M | -1.12M | -- |
| Total Operating Expenses | 84.19M | 74.83M | 65.92M | 57.76M | 48.72M |
| Operating Income | -84.19M | -74.83M | -65.92M | -57.76M | -48.72M |
| Income Before Tax | -78.54M | -67.51M | -57.95M | -50.29M | -40.21M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -78.54 | -67.51 | -57.95 | -50.29 | -40.21 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -78.54M | -67.51M | -57.95M | -50.29M | -40.21M |
| EBIT | -84.19M | -74.83M | -65.92M | -57.76M | -48.72M |
| EBITDA | -83.96M | -74.52M | -65.50M | -57.24M | -48.13M |
| EPS Basic | -5.98 | -5.51 | -4.76 | -4.23 | -3.66 |
| Normalized Basic EPS | -3.78 | -3.65 | -3.18 | -2.85 | -2.50 |
| EPS Diluted | -5.98 | -5.51 | -4.76 | -4.23 | -3.66 |
| Normalized Diluted EPS | -3.78 | -3.65 | -3.18 | -2.85 | -2.50 |
| Average Basic Shares Outstanding | 53.27M | 48.93M | 48.64M | 47.45M | 43.56M |
| Average Diluted Shares Outstanding | 53.27M | 48.93M | 48.64M | 47.45M | 43.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |